United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting

A Cross-Sectional Patient-Reported Study To Assess The Patient Preference Of Treatment Administration Setting, Impact On Health-Related Quality Of Life, Work Productivity, Wider Societal Costs And Healthcare Utilisation For Patients With Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Prescribed Somatuline® Autogel® In A Homecare Setting and Hospital Setting.

The aim of the study is to generate real-world evidence to describe the patient experience of administration of Somatuline® Autogel® (lanreotide) in homecare and hospital settings, and the associated impact on healthcare utilisation, societal cost, work productivity and health-related quality of life (HRQoL)

Inclusion Criteria:

• Patients with a diagnosis of GEP-NETs
• Patients on prescribed lanreotide Autogel®;
• Patients who have switched from hospital to homecare administration setting at least 2 months ago
• Patients judged to be on a stable dose; 120mg for tumour control or >1 injection at same dose for symptom control

Exclusion Criteria:

• Patients who decline or lack capacity to consent to participate in the study